
EKSO Stock Forecast & Price Target
EKSO Analyst Ratings
Bulls say
Ekso Bionics Holdings Inc. demonstrated a robust recovery in its financial performance for the third quarter of 2025, with total revenues reaching $4.22 million, reflecting a notable 105% quarter-over-quarter growth compared to $2.06 million in the second quarter. The company also saw a significant improvement in gross margins, which increased to 60.3% from 39.8% in the previous quarter. Additionally, the announcement of a non-binding merger agreement with Applied Digital Cloud may further enhance its operational capabilities and market position, contributing to a favorable outlook for the company's stock.
Bears say
Ekso Bionics Holdings Inc. experienced a revenue miss in the prior quarter, attributed to order delays in enterprise sales totaling $1.5 million, which has contributed to a negative outlook on the stock. The company reported 3Q25 revenues of $4.23 million and a narrower net loss of $0.54 per share, which, while slightly better than consensus estimates, does not indicate a robust financial recovery. Overall, the recent downgrade to a Neutral rating coupled with operational challenges suggests ongoing uncertainties surrounding the company's ability to meet growth expectations in its targeted markets.
This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.
EKSO Analyst Forecast & Price Prediction
Start investing in EKSO
Order type
Buy in
Order amount
Est. shares
0 shares